PubMed_ArguminSci  

PubMed:26253900 JSONTXT 8 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 129-255 DRI_Approach denotes The leucine-rich repeat kinase 2 (LRRK2) mutation G2019S is one of the most common genetic causes in Parkinson's disease (PD).
T2 256-273 DRI_Challenge denotes The penetrance of
T3 287-412 DRI_Challenge denotes is incomplete and is age-dependent, therefore, it has been speculated that environmental toxins and aging could contribute to
T4 434-450 DRI_Challenge denotes PD pathogenesis.
T5 451-535 DRI_Approach denotes To prove this speculation, we performed a longitudinal investigation in mice bearing
T6 549-558 DRI_Approach denotes mutation.
T7 559-562 DRI_Background denotes BAC
T8 576-696 DRI_Background denotes transgenic (Tg) mice and their wildtype (Wt) littermates were treated with lactacystin, a specific proteasome inhibitor.
T9 697-728 DRI_Background denotes The susceptibilities of mice to
T10 763-841 DRI_Background denotes dopaminergic (DAergic) degeneration were evaluated, at 5 and 12 months of age.
T11 842-1011 DRI_Outcome denotes We found that lactacystin treatment caused a greater decline of striatal DA content in the Tg mice at either 5 or 12 months of age than their age-matched Wt littermates.
T12 1012-1192 DRI_Background denotes Moreover, the lactacystin-treated Tg or Wt mice at 12 months of age lose much more nigral tyrosine hydroxylase (TH)-positive neurons than the mice at 5 months of age, indicating an
T13 1216-1230 DRI_Background denotes neurotoxicity.
T14 1231-1421 DRI_Background denotes Additionally, stereotactic injection of lactacystin induced a dramatic increase of activated microglia in substantia nigra of mice at 12 months of age, compared with mice at 5 months of age.
T15 1422-1575 DRI_Outcome denotes In summary, our study suggests that expression of the G2019S mutation in the mouse LRRK2 gene confers an age-associated high susceptibility to proteasome
T16 1617-1630 DRI_Outcome denotes degeneration.